# Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients

> **NCT01322789** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University of Sao Paulo** · enrollment: 10 (estimated)

## Conditions studied

- Diabetes Mellitus, Insulin-Dependent

## Interventions

- **BIOLOGICAL:** Intravenous Mesenchymal stem cell infusion

## Key facts

- **NCT ID:** NCT01322789
- **Lead sponsor:** University of Sao Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-09
- **Primary completion:** 2015-11
- **Final completion:** 2015-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2011-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01322789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01322789, "Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01322789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*